- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.12.25 | TRANSTHERA-B (02617.HK) Plummets 17% with Surging Trading Vol. | 1 | AASTOCKS | ||
| TRANSTHERA SCIENCES Aktie jetzt für 0€ handeln | |||||
| 19.12.25 | TransThera Sciences (Nanjing) Inc.: New Drug Application For Tinengotinib Tablets Accepted By The National Medical Products Administration | 108 | PR Newswire | NANJING, China and GAITHERSBURG, Md., Dec. 18, 2025 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced that the new drug application... ► Artikel lesen | |
| 19.12.25 | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR TINENGOTINIB TABLETS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | 2 | HKEx | ||
| 17.12.25 | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT PUBLICATION OF CLINICAL RESULTS OF OUR CORE PRODUCT TINENGOTINIB AGAINST CHOLANGIOCARCINOMA | - | HKEx | ||
| 03.12.25 | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE NATIONAL MEDICAL PRODUCTS ... | - | HKEx | ||
| 03.11.25 | Neurocrine pens $880M deal with China's TransThera for red-hot immunology target | 12 | FierceBiotech | ||
| 03.11.25 | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT COLLABORATION WITH NEUROCRINE | 4 | HKEx | ||
| 20.10.25 | TRANSTHERA-B (02617): INSIDE INFORMATION ANNOUNCEMENT PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANY | 1 | HKEx | ||
| 25.09.25 | A wild ride for TransThera investors: what's the story? | 1 | Bamboo Works | ||
| 19.09.25 | TRANSTHERA-B (02617): INTERIM REPORT 2025 | 2 | HKEx | ||
| 16.09.25 | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS | 1 | HKEx | ||
| 10.09.25 | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT PHASE II IND APPROVAL OF TINENGOTINIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF PREVIOUSLY TREATED ... | - | HKEx | ||
| 04.09.25 | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF TINENGOTINIB IN COMBINATION WITH AKESO'S (CADONILIMAB, ... | - | HKEx | ||
| 25.08.25 | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT INCLUSION OF THE COMPANY AS A CONSTITUENT OF THE HANG SENG INDEX SERIES | 1 | HKEx | ||
| 25.08.25 | TRANSTHERA-B (02617): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 | 1 | HKEx | ||
| 25.08.25 | TRANSTHERA-B (02617): CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG | - | HKEx | ||
| 13.08.25 | TRANSTHERA-B (02617): DATE OF BOARD MEETING | - | HKEx | ||
| 04.08.25 | TRANSTHERA-B (02617): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 4 AUGUST 2025 | - | HKEx | ||
| 11.07.25 | TRANSTHERA-B (02617): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, 4 AUGUST 2025 | 2 | HKEx | ||
| 11.07.25 | TRANSTHERA-B (02617): NOTICE OF ANNUAL GENERAL MEETING | 2 | HKEx |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|
TRANSTHERA SCIENCES NANJING INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSTHERA SCIENCES NANJING INC finden Sie auf Wallstreet Online.